Affiliation:
1. Medizinische Klinik und Poliklinik II and
2. Mildred Scheel Early Career Center, Universitätsklinikum Würzburg, Würzburg, Germany
Abstract
Abstract
The treatment of multiple myeloma (MM) is currently being redefined by humoral and cellular immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy as a result of the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation. Today, monoclonal antibodies comprise the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most potent single agents for MM treatment. Herein, we present our assessment of and vision for MM immunotherapy in the short and midterm.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference71 articles.
1. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study;Moreau;Lancet,2019
2. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN [published online ahead of print 23 April 2020];Voorhees;Blood
3. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma;Mateos;N Engl J Med,2018
4. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma;Facon;N Engl J Med,2019
5. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma;Usmani;Blood,2019
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献